Press Releases

Gyroscope Therapeutics Announces Research Collaboration Agreement with Children’s Medical Research Institute to Develop Novel Gene Therapy Capsids

Gyroscope Therapeutics Postpones Initial Public Offering

Gyroscope Therapeutics Announces Launch of Initial Public Offering

Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United States

Gyroscope Therapeutics Announces Additional Financing Plans

Gyroscope Therapeutics Announces $148 Million Raised in Series C Financing

Gyroscope Therapeutics Appoints Jessica Stitt as Chief Financial Officer

Gyroscope Therapeutics Announces Positive Interim Data from Phase I/II FOCUS Trial of Investigational Gene Therapy GT005

Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases

Gyroscope Therapeutics Announces Appointments of Industry Veterans in Gene Therapy, Ophthalmology and Biopharmaceuticals to its Board of Directors

Gyroscope Therapeutics Announces First Patient Dosed in Phase II HORIZON Trial Evaluating Investigational Gene Therapy, GT005, in People with Dry Age-Related Macular Degeneration

Gyroscope Therapeutics Announces First Patient Received Investigational Gene Therapy GT005 Via Orbit Subretinal Delivery System in Ongoing Phase I/II FOCUS Trial

Researchers Call For More Than 6,000 People To Donate A Saliva Sample To Help Them Better Understand One Of The World’s Leading Causes Of Blindness

Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005, an Investigational Gene Therapy for Dry Age-Related Macular Degeneration

Gyroscope Therapeutics Announces Appointment of Sean Bohen to the Board of Directors

Gyroscope Therapeutics Announces FDA Clearance for Orbit Subretinal Delivery System

Gyroscope Therapeutics Announces Initiation of Phase II Programme Evaluating its Investigational Gene Therapy, GT005, for Dry Age-Related Macular Degeneration

Gyroscope Therapeutics Announces Appointment of Leaders in Retinal Disease, Gene Therapy and the Complement System to its Clinical and Scientific Advisory Boards

Gyroscope Therapeutics Strengthens Senior Leadership Ahead of Next Stage of Company Growth

Gyroscope Therapeutics secures £50.4 million in Series B financing to continue clinical development of gene therapies and surgical delivery systems for retinal diseases

Gyroscope Therapeutics merges with Orbit Biomedical creating a leading retinal gene therapy company

Gyroscope Therapeutics announces first patient dosed in Phase I/II FOCUS study in dry AMD

Gyroscope Therapeutics led consortium secures INNOVATE UK funding to develop a suspension platform for cost effective manufacture of novel AAV gene therapies

Gyroscope Therapeutics appoints Dr Soraya Bekkali as Chief Executive Officer

Contact

Our Science

Gene Therapies

Clinical Trials